Clinical Trial

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

Recruiting
View on ClinicalTrials.gov →
Summary
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-07-09; most recent amendment 2024-07-23.
Status change: Active, Not Recruiting → Recruiting 2023-02-14
Status change: Not Yet Recruiting → Active, Not Recruiting 2019-10-09
Trial Details
NCT Number NCT04014374
Lead Sponsor Kyowa Kirin, Inc.
Conditions Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
Enrollment 150 participants
Start Date 2019-09-10
Primary Completion 2030-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2024-07-24